Extending the Span of Time in nAMD and DME Management

Rishi P. Singh, MD

President, Cleveland Clinic Martin North and South Hospitals

Stuart, FL

Center for Ophthalmic Bioinformatics, Cole Eye Institute, Cleveland Clinic

Professor of Ophthalmology, Lerner College of Medicine, Case Western Reserve University

Cleveland, OH

John W. Kitchens, MD

Vitreoretinal Surgeon

Retina Associates of Kentucky

Lexington, KY

Intravitreal anti-vascular endothelial growth factor (VEGF) therapies have significantly enhanced visual and anatomical outcomes for patients with diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). However, real-world outcomes are not always comparable to those demonstrated in pinnacle clinical studies in part due to treatment burden and lack of patient adherence. Corticosteroids are another effective therapeutic option for those patients with DME, but these agents are often not effectively integrated into clinical management protocols. The continued refinement of treatment protocols with FDA-approved therapies and the integration of novel delivery systems and agents with unique mechanisms of action into practice are means of addressing the treatment burden through extending the interval between dosing schedules while maintaining initial visual acuity gains. In this continuing medical education activity, experts in the field assess new injectable-based protocols that lessen the treatment burden as well as evaluate new surgical interventions and procedures that can optimize the treatment of patients with nAMD and DME.

Introduction and Pretest

Rishi Singh, MD

Extending the Span of Time Using Injectables in nAMD and DME Management

Rishi Singh, MD

Case Presentation: Treating Patients With nAMD

Rishi Singh, MD

Extending the Span of Time Using Surgical Delivery Systems

John W. Kitchens, MD

Case Presentation: Refilling the PDS in the Management of Patients With nAMD

John W. Kitchens, MD

Posttest and LIVE Question & Answer

Upon successful completion of this activity, participants should be better able to:

• Assess new injectable-based protocols that lessen the treatment burden of patients with nAMD and DME.
• Describe new surgical interventions and procedures that can optimize the treatment of patients with nAMD and DME.

The intended audience for this activity is ophthalmologists and other health care professionals involved in the management of patients with nAMD and/or DME.

This continuing medical education activity is provided by Vindico Medical Education.

This activity is supported by an educational grant from Genentech, a member of the Roche Group.

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Vindico Medical Education designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Vindico Medical Education adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will be mitigated prior to the commencement of the activity.

Faculty, topics, program schedule, and credit hours are subject to change. Recording of any manner is prohibited without written permission from Vindico Medical Education, Office of Medical Affairs and Compliance.

Contact Us:

Email: [email protected]

Host or Publisher Vindico Medical Education